| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 34 | — | 17.2x | Bottom tier | |
Growth | 3 | -8.2% | 7.1% | Bottom tier | |
Quality | 43 | -11.0% | 4.5% | Around median | |
Safety | 69 | — | 2.6x | Top tier | |
Capital Return | 38 | 0.00% | 0.19% | Bottom tier | |
Momentum | 60 | 3.4% | 0.5% | Around median | |
Sentiment | 40 | 13 | 3 | Bottom tier |
10-year US Treasury yield 5.29% as of 2026-09-30. Estimates computed from company data and analyst targets, not investment advice.
BioNTech SE develops and commercializes treatments and vaccines based on multiple immunological technologies, including mRNA vaccines, next-generation immunomodulators, and antibody-drug conjugates. Its current commercial revenue comes primarily from the COVID-19 vaccine developed with Pfizer, while its oncology portfolio remains in clinical development; the company also receives collaboration revenue and milestone payments, including a €613 million payment from the BMS collaboration that was expected to be recognized in Q3 of fiscal year 2026.
In Q2 of fiscal year 2026, revenue fell to €106 million from €261 million in the corresponding period, a decline of approximately 59%, due to weak U.S. demand for the COVID-19 vaccine and a nonrecurring compensatory payment from Pfizer in the comparative period. Adjusted research and development expenses were €477 million versus €509 million, while selling, general, and administrative expenses rose to €198 million from €137 million due to the expansion of operations and infrastructure and the costs of preparing to launch oncology programs. The context did not include a figure for quarterly net income or its margin, but the fact that the stated adjusted operating expenses exceeded quarterly revenue illustrates the continued investment burden before the oncology portfolio becomes commercial products.
On an annual basis, fiscal year 2025 revenue rose to $2.9 billion from $2.8 billion in fiscal year 2024, while gross profit remained at $2.2 billion, equivalent to a gross margin of approximately 76%. In contrast, the net loss widened to $1.1 billion from $665.3 million, and the loss per share was $4.70, after the company had generated $930.3 million in net income in fiscal year 2023. This combination reflects a difficult financial transition from pandemic vaccine profits to funding a broad oncology portfolio that has not yet begun generating revenue from multiple products.
The average analyst price target is $130.43, with a “Buy” consensus and a wide range of $96 to $155; the average exceeds the upper end of the 52-week range of $124 by approximately 5%, while the highest target exceeds it by approximately 25%. No useful price-to-earnings ratio is available because of the fiscal year 2025 loss of $1.1 billion, so the valuation rests heavily on liquidity and the oncology portfolio; conversely, weak demand for COVID-19 vaccines and the termination of the colorectal cancer trial on August 28, 2026 justify the wide range of analyst targets and the continued clinical risk premium.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
Current commercial revenue comes primarily from the COVID-19 vaccine developed with Pfizer, with additional contributions from collaboration agreements and milestone payments. Q2 fiscal year 2026 revenue was approximately €106 million, down from €261 million in the corresponding period due to weak U.S. demand and a nonrecurring effect in the comparative period. The company expected to recognize a €613 million BMS collaboration payment in Q3 of fiscal year 2026. Oncology assets such as pumitamig, gotistobart, and BNT113 remain experimental and have not yet become a multi-product commercial portfolio.
On August 4, 2026, the company lowered its expected revenue range to €1.6–€1.9 billion. Management said approximately 80% of the adjustment was attributable to weak COVID-19 vaccination rates and the regulatory and healthcare environment, with a more pronounced effect in Germany due to the use of previously manufactured doses. The remaining portion was primarily related to the deferral of milestone revenue from a licensed program beyond fiscal year 2026. The company maintained its selling, general, and administrative expense guidance at €700–€800 million and lowered its adjusted research and development range to €2.0–€2.3 billion.
Automated analysis for informational purposes only — not investment advice.
pumitamig is a bispecific antibody targeting PD-L1 and VEGF-A that BioNTech is developing with BMS, and the company is advancing it through four registrational programs in lung cancer. In ROSETTA Lung-02, the confirmed objective response rate was 62.5% among 40 evaluable patients and reached 47.6% among patients with PD-L1 expression below 1%. Global data in small cell lung cancer also showed a disease control rate of 100% and a confirmed response rate of 76%. Nevertheless, management acknowledged on August 4, 2026 that no head-to-head comparison demonstrates differentiation, so phase 3 results will remain decisive.
On August 28, 2026, BioNTech terminated a mid-stage trial of an mRNA-based colorectal cancer vaccine, and the news was followed by a decline of approximately 9% to 10% in the stock. The decision represents a setback for one path of transferring mRNA technology into oncology and confirms that having multiple programs does not eliminate clinical failure risk. In contrast, the separate autogene cevumeran program in colorectal cancer continues after the safety monitoring board recommended in June 2026 that its trial proceed without modification. According to the August 4, 2026 call, the final readout for that program was event-driven and expected in 2027.
Cash and cash equivalents and security investments totaled €16.6 billion at the end of Q2 of fiscal year 2026, up from €16 billion on June 30, 2025. In the first half of fiscal year 2026, adjusted research and development expenses totaled €1.004 billion as funding continued for pumitamig, gotistobart, and antibody-drug conjugate programs. The company also began a repurchase program of up to $1 billion and had executed $152 million of it as of August 4, 2026. These resources provide room to fund trials and commercial preparations, but they do not eliminate the risk of widening losses if approvals are delayed or pivotal readouts fail.
